Virax Biolabs Group Ltd (VRAX) stock
VRAXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends March 31
$0.33−0.05 (-12.89%)
Close on Nov 20, 2026Market cap $192.24KP/E –Yield –
Virax Biolabs gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
For fiscal 2026 it was $7.69K. The highest annual figure on record is $50.59K in fiscal 2024.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | $7.69K | – |
| FY2025 | Mar 31, 2025 | -$53.07K | -204.9% |
| FY2024 | Mar 31, 2024 | $50.59K | – |
| FY2023 | Mar 31, 2023 | -$1.37K | – |
| FY2021 | Mar 31, 2021 | -$9.43K | – |
See a number that looks wrong?